VIEW
IN BROWSER
EDITOR'S
NOTE: Big4Bio newsletters will not be
published from Dec 16, 2025, to Jan 4, 2026; they
will resume distribution on Monday, Jan 5, 2026.
|
 |
| DEcember
15, 2025 |
| Covering
Life Sciences Drugs, Diagnostics, Devices,
Digital Health |
|
|
|
* may need subscription to view |
 |
| Boston's
most flexible contract vivarium
lab space: Start with a few study
cages and grow. |
|
Learn More
→ |
|
|
- Abpro: Submission of an IND Application to
Initiate a Phase 1 Clinical Trial of T Cell Engager
ABP-102/CT-P72 for HER2-positive Cancers More
- Aviceda Therapeutics: Phase 2b SIGLEC
Results for AVD-104 in Geographic Atrophy More
- Fondazione Telethon and Orphan Therapeutics
Accelerator: Sign Memorandum of Understanding
to Pioneer Non-Profit Commercial Access Model
for Ultra-Rare Disease Gene Therapy in the US
More
- Innoviva Specialty Therapeutics: U.S. FDA
Approves NUZOLVENCE (zoliflodacin), a
First-in-Class, Single-dose, Oral Antibiotic
for the Treatment of Uncomplicated
Urogenital Gonorrhea in Adults and
Adolescents More
- Insulet: Expands Omnipod U.S. Recycling
Program, Diverting Millions of Pods From
Landfills and Creating a More Sustainable
Future More
- Manifold Bio: Expands Leadership Team to
Drive Its AI + In Vivo Targeted Biologics
Platform More
- Moderna: EMA Committee for Medicinal
Products for Human Use Adopts Positive Opinion
Recommending Authorization of mNEXSPIKE
(COVID-19 Vaccine, mRNA) More
- Thermo Fisher Scientific: Expands Gibco
Bacto Portfolio With Next-Generation,
Chemically Defined Media to Boost E. coli
Biomanufacturing Productivity More
- Zenas BioPharma: Partner, InnoCare Pharma,
Announces Achievement of Primary Endpoint in
Phase 2b Study of Orelabrutinib, a BTK
Inhibitor, for Systemic Lupus Erythematosus More
|
|
 |
 |
The
Charles River CFO Advantage
Reassessing your business plan?
We provide financial leadership.
Smart. Nimble. Flexible. |
|
Learn More
→ |
|
|
|
- Attivare Therapeutics: Awarded $6.6 Million
Grant to Advance Durable Malaria Vaccine More
- Cambridge Biotech Receives $255M in Sale
of Spinout to BMS More*
- CAMP4 Therapeutics: Inducement Grants Under
Nasdaq Listing Rule 5635(c)(4) More
- Enveric Biosciences: Closing of Exercise of
Warrants for $3.1 Million Gross Proceeds More
- Get Full Access to BYTE51 Life Sciences
Intelligence for 50% Off More
- JPM
Week Conference Readiness Packages (Big4Bio
Subscriber Discount) More
- NANOBIOTIX: Will Join CAC Mid 60 and SBF 120
Indices on Euronext Paris More
- Navigating Post-IPO Financial Reporting More
- Scholar
Rock: New Employee Inducement Grants Under
Nasdaq Listing Rule 5635(c)(4) More
- Vicarious Surgical: Full Year 2026 Cash Burn
Guidance More
- Vor Bio: $150 Million Private Placement More
|
|
 |
Pace®
Life Sciences
The CDMO That Takes You Further.
Your partner for Product
Development, Manufacturing,
Analytical Testing, Regulatory
Consulting & Operational
Support. |
|
Learn More
→ |
|
|
|
- BiotechTV: CREATE Medicines’ Platform Allows
It to Program CARs Into Multiple Immune Cell
Types Inside the Body, and is Redosable. While
This Includes CAR-T, They Believe That "In
Vivo Is More Than T-Cells." Video
- Boston's Lab Developers Are Falling Out Of
Love With Spec Suites More*
- Subscribe to LifeSci Startup for
Updates on US Startups More
- The Big4Bio Podcast: Every Moment
Matters: Integrating AI into Drug Discovery
Podcast
|
|
|
DISCOVER COMPANIES |
|
Big4Bio: Boston Life Science
Company Directory |
|
Locate a specific company or
explore new companies in life
science. |
|
Explore
our Company Directory
|
Provided courtesy
of
 |
|
|
|
Feature your company |
| Apply
to have your company
showcased by Big4Bio |
|
|
|
|
|
 |
|
Premier Executive Search and
Talent Advisory Firm Slone
Partners Launches Fractional
Talent Service to Deliver
On-Demand Leaders and Specialists
|
|
Learn More
→ |
|
|
- M&A in Life Sciences: The Turning
Tide – Why Now is a Strategic Inflection for
Biopharma and Biotech More
- ICYMI: CEO’s Perspective: Big Moves Come
with Big Responsibility More
- ICYMI: CEO’s Perspective: The High Cost of
Job Hopping More
- ICYMI: Elevating Executive Presence: A
Blueprint for Life Sciences and Biotech
Leaders More
- ICYMI: The Power of Peer Learning - Why Even
Top Biotech Leaders Need Mentorship More
- ICYMI: What’s Next in Precision Medicine:
Leadership Challenges and Opportunities More
- The Rise of Fractional Talent in Life
Sciences: What to Expect in 2026 More
|
|
 |
|
|
|
You are
receiving this email because
you signed up for one of our
newsletters at Big4Bio.com,
signed up at one of our
partner or sponsor events,
or given as a gift
subscription by your firm or
organization. Unsubscribe
Big4Bio:Boston,
all rights reserved 2025
© 2025
Big4Bio, a division of
BigBio Communications. All
rights reserved.
|
|
|
|
|
